Your browser version may not work well with NCBI's Web applications. More information here...
1: Ann Rheum Dis. 2007 Feb;66(2):143-50. Epub 2006 Oct 26.Click here to read Links

Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. josef.smolen@wienkav.at

A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

PMID: 17068064 [PubMed - indexed for MEDLINE]

Patient Drug Information